Urology Times

06/17/2026

The FDA has approved tebipenem pivoxil (Utebzi) for adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, marking the first approval of an oral carbapenem therapy in the US.

The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin.

06/16/2026

WATCH: Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary antitumor activity of 225Ac-PSMA-617 in patients with mCRPC.

Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

06/12/2026

In the latest episode of The UroOnc Minute, host Adam Weiner, MD, sits down with Carissa Chu, MD, to discuss the evolving understanding of variant histology in bladder cancer and its implications for clinical practice.

In this episode of The UroOnc Minute, Carissa Chu, MD, discusses the prevalence, biology, prognostic significance, and emerging molecular targets of variant histologies in bladder cancer.

06/10/2026

The FDA has approved Radiomedix's generic Ga-68 PSMA-11, a radioactive diagnostic agent for PET imaging of PSMA-positive lesions in patients with prostate cancer.

The approval adds another commercially available source of the PSMA-targeted radiotracer.

06/09/2026

WATCH: Nicole Miller, MD, FACS, discusses her approach to evaluating and managing patients who experience persistent or recurrent lower urinary tract symptoms after treatment for BPH.

In this video, Nicole L. Miller, MD, FACS, discusses her approach to assessing patients after prior treatment failure for benign prostatic hyperplasia.

06/05/2026

Ever wondered what a Urology Times Clinical Forum actually feels like? We'll let the experience speak for itself.

Hear what Sia Daneshmand, M.D., the moderator who brought it all to life, has to say about the energy, expertise, and conversation that define a Urology Times Clinical Forum. Think great food, genuine conversation, and peer-to-peer education all in one room.

While this particular forum took place in Los Angeles, our Clinical Forums happen across the country — each one designed to deliver the same high-caliber education that keeps urologists at the forefront of their field.

Intimate settings. Relevant topics. Real dialogue.

Curious what we've covered? Explore past forums and stay tuned for upcoming dates: https://hubs.li/Q04k9q-_0

06/03/2026

The FDA has approved Titan Prime, an inflatable pe**le prosthesis for patients with erectile dysfunction.

Titan Prime will be available in the US via a phased launch beginning in late 2026.

06/01/2026

The FDA has approved cefepime and zidebactam for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis, caused by susceptible Gram-negative pathogens.

The FDA approved ZAYNICH for adult complicated UTI after ENHANCE-1 showed an 89.0% response rate at test of cure.

05/31/2026

PROTEUS: One year of perioperative apalutamide plus ADT significantly improved MFS, pathological complete response or minimal residual disease, EFS, and time to first subsequent therapy vs placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer.

"Compared to placebo [plus] ADT, apalutamide [plus] ADT showed 9 times more pCR/MRD, a 20% improved MFS, a 29% reduction in prostate cancer recurrence, and a 3-year improvement in time to subsequent therapy," said Mary-Ellen Taplin, MD, FASCO.

05/30/2026

: Adding intravesical recombinant BCG to perioperative chemo-immunotherapy yielded a pCR rate of 68% in patients with MIBC, meeting the primary end point of the phase 2 SAKK 06/19 trial.

"Twenty-seven of forty patients achieved a pCR amounting to a rate of sixty-eight percent. Therefore, the null hypothesis could be rejected," said Richard Cathomas, MD.